Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6481 to 6495 of 7680 results

  1. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued [GID-DT9]

    Diagnostics guidance
    Discontinued

  2. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development [GID-TAG388] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued [GID-TAG400]

    Technology appraisal guidance
    Discontinued

  4. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued [GID-TAG416]

    Technology appraisal guidance
    Discontinued

  5. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued [GID-TA10970]

    Technology appraisal guidance
    Discontinued

  7. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued [GID-TAG401]

    Technology appraisal guidance
    Discontinued

  8. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued [GID-TAG391]

    Technology appraisal guidance
    Discontinued

  9. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued [GID-TAG405]

    Technology appraisal guidance
    Discontinued

  10. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued [GID-TA11206]

    Technology appraisal guidance
    Discontinued

  11. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued [GID-TA11207]

    Technology appraisal guidance
    Discontinued

  12. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued [GID-TA10140]

    Technology appraisal guidance
    Discontinued

  13. Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

    Discontinued [GID-TA10637]

    Technology appraisal guidance
    Discontinued

  14. Zio XT for detecting cardiac arrhythmias

    In development [GID-MT591] Expected publication date: TBC

    Medical technologies guidance
    In development

  15. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    In development [GID-TA10996] Expected publication date: TBC

    Technology appraisal guidance
    In development